Literature DB >> 10673520

Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.

F Morschhauser1, J M Cayuela, S Martini, A Baruchel, P Rousselot, G Socié, P Berthou, J P Jouet, N Straetmans, F Sigaux, P Fenaux, C Preudhomme.   

Abstract

PURPOSE: Most studies using various reverse-transcription polymerase chain reaction (RT-PCR) techniques reported that the detection of the AML1-ETO fusion transcript was a common finding in long-term complete remission (CR) in acute myeloid leukemia (AML) with t(8;21) translocation. However, larger prospective studies with interlaboratory quality control may be important to investigate more precisely the clinical usefulness of studying minimal residual disease with RT-PCR in t(8;21) AML. PATIENTS AND METHODS: We collected 223 marrow samples from 51 patients with t(8;21) AML diagnosed in five centers and tested all samples by two different RT-PCR techniques (a nested technique and a one-step technique, with a sensitivity of 10(-6) and 10(-5), respectively) in two different laboratories.
RESULTS: Samples from 14 patients in long persistent CR (median follow-up duration, 112 months) were taken at least twice, and all were PCR-negative by both techniques. Samples were prospectively taken from 37 patients after achievement of first CR and/or second CR, before intensive consolidation treatment, and every 3 to 6 months after completion of therapy. Patients who converted to PCR negativity with the one-step technique (60%) or both techniques (48%) after CR achievement had a longer CR duration than those with persistently positive PCR results (two-sided log-rank test, P =.0001). Patients who became PCR-negative with the one-step technique before intensive consolidation (23%) had a lower relapse rate (11% v 72%) and a longer CR duration than those who remained persistently PCR-positive at that point (two-sided log-rank test, P =.0015).
CONCLUSION: Patients with AML with t(8;21) in long-term remission were all PCR-negative. In prospectively studied patients, a good correlation was found between negative PCR results and absence of relapse. Early negative results with the one-step RT-PCR technique, before consolidation treatment, seemed to carry an especially good prognosis, suggesting that RT-PCR analysis could help in choosing the type of consolidation therapy in patients with t(8;21) AML.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10673520     DOI: 10.1200/JCO.2000.18.4.788

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

Review 1.  Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy.

Authors:  Sebastian Schwind; Madlen Jentzsch; Enrica Bach; Sebastian Stasik; Christian Thiede; Uwe Platzbecker
Journal:  Curr Treat Options Oncol       Date:  2020-01-30

2.  The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia.

Authors:  Juan Ouyang; Maitrayee Goswami; Guilin Tang; Jie Peng; Farhad Ravandi; Naval Daver; Mark Routbort; Sergej Konoplev; Pei Lin; L Jeffrey Medeiros; Jeffrey L Jorgensen; Sa A Wang
Journal:  Am J Hematol       Date:  2015-04-02       Impact factor: 10.047

3.  Recurrence of acute myelogenous leukemia with the same AML1/ETO breakpoint as at diagnosis after complete remission lasting 15 years: analysis of stored bone marrow smears.

Authors:  Norifumi Tsukamoto; Masamitsu Karasawa; Yoko Tanaka; Akihiko Yokohama; Hideki Uchiumi; Takafumi Matsushima; Hirokazu Murakami; Yoshihisa Nojima
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

4.  Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).

Authors:  Lixia Zhang; Qinghua Li; Wei Li; Bingcheng Liu; Ying Wang; Dong Lin; Chunlin Zhou; Chengwen Li; Jianxiang Wang; Yingchang Mi
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

5.  Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia.

Authors:  John A Liu Yin; Lindsay Frost
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

6.  Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.

Authors:  Juan Ouyang; Maitrayee Goswami; Jie Peng; Zhuang Zuo; Naval Daver; Gautam Borthakur; Guilin Tang; L Jeffrey Medeiros; Jeffrey L Jorgensen; Farhad Ravandi; Sa A Wang
Journal:  Am J Clin Pathol       Date:  2016-06-12       Impact factor: 2.493

7.  Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.

Authors:  Håkon Reikvam; Kimberley Joanne Hatfield; Astrid Olsnes Kittang; Randi Hovland; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2011-05-03

8.  Significance of spatial organization of chromosomes in the progression of acute myeloid leukemia.

Authors:  Xueli Tian; Yanfang Wang; Dieyan Chen; Xiaoyan Ke; Wanyun Ma
Journal:  Chin J Cancer       Date:  2017-04-20

9.  Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Shuang Fan; Meng-Zhu Shen; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Xiao-Su Zhao; Ya-Zhen Qin; Ying-Jun Chang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Dong Mo
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

10.  Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.

Authors:  Eun Kyung Cho; Soo Mee Bang; Jeong Yeal Ahn; Seung Min Yoo; Pil Whan Park; Yieh Hea Seo; Dong Bok Shin; Jae Hoon Lee
Journal:  Korean J Intern Med       Date:  2003-03       Impact factor: 2.884

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.